文献速递泌尿男性生殖肿瘤

高瘤负荷与低瘤负荷转移性激素敏感性前列腺癌中BRCA1/2及同源重组修复基因改变的发生率及对结局的影响

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.
PubMed 文献 · Ann Oncol · 2025-06-02

研究纳入2018年1月至2023年12月诊断的556例转移性激素敏感性前列腺癌(mHSPC)患者,进行体细胞/胚系DNA配对测序。159例(28.6%)存在HRR基因改变,其中BRCA突变69例(12.4%),HRR非BRCA突变90例(16.2%)。BRCA突变患者在所有终点上结局均显著更差(所有比较P<0.005),且该预后差异在低瘤负荷与高瘤负荷亚组中均存在,独立于雄激素受体通路抑制剂或紫杉类治疗。

要点

  • 556例mHSPC中HRR基因改变占28.6%,BRCA突变占12.4%,HRR非BRCA突变占16.2%。
  • BRCA突变患者影像学无进展生存、去势抵抗时间及总生存均显著更差(所有比较P<0.005)。
  • BRCA/HRR状态对预后的影响在低瘤负荷和高瘤负荷亚组中均存在,且独立于ARPI或紫杉类治疗。

核心结论

  • HRR基因改变、尤其是BRCA改变的存在显著恶化mHSPC预后,与疾病瘤负荷或治疗方案无关。
  • 这些发现强调将肿瘤生物学整合到mHSPC准确风险分层以及新治疗策略和随访设计中的重要性。

研究设计与样本

  • 纳入2018年1月至2023年12月诊断的符合条件mHSPC患者,进行体细胞/胚系配对DNA测序。
  • 共556例患者,按HRR基因改变分为BRCA、HRR非BRCA、非BRCA或非HRR亚组。
  • 采用逆概率治疗加权模型控制治疗方式和基线特征后评估突变与结局的关联。
  • 报告所有亚组的影像学无进展生存、去势抵抗时间和总生存。

主要发现

  • 556例中159例(28.6%)存在HRR基因改变:BRCA突变69例(12.4%),HRR非BRCA突变90例(16.2%)。
  • mHSPC为同步性者451例(81.1%),按CHAARTED标准分类为高瘤负荷者306例(55%)。
  • 在HRR亚组内,BRCA突变患者在所有终点上结局均显著更差(所有比较P<0.005)。
  • 按BRCA和HRR状态区分的预后差异在低瘤负荷和高瘤负荷亚组中均可见,且独立于雄激素受体通路抑制剂或紫杉类治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alterations in BRCA1/2 (BRCA) and other homologous recombination repair (HRR) genes have a negative impact on outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Poly(adenosine diphosphate-ribose) polymerase inhibitors, the only treatment demonstrated to improve the prognosis of patients with mCRPC, are also being developed for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). To fully assess their potential benefit in this setting, it is essential to understand how BRCA and HRR defects may influence the prognosis of conventionally treated patients with low and high disease volume. PATIENTS AND METHODS: Eligible mHSPC patients diagnosed between January 2018 and December 2023 underwent paired somatic/germline DNA sequencing. Cases with alterations in one or more HRR genes were classified as BRCA, HRR non-BRCA, non-BRCA or non-HRR. Radiographic progression-free survival, time to castration resistance and overall survival were reported for all subgroups; associations between mutations and outcomes were assessed after controlling for treatment modality and baseline characteristics using inverse probability of treatment weighting models. RESULTS: Of 556 patients, 159 (28.6%) had HRR gene alterations: 69 (12.4%) with BRCA and 90 (16.2%) with HRR non-BRCA mutations. mHSPC was synchronous in 451 patients (81.1%) and was classified as high-volume (CHAARTED criteria) in 306 (55%) patients. Within the HRR subgroup, patients with BRCA mutations had significantly worse outcomes across all endpoints (P < 0.005 for all comparisons). Differences in prognosis by BRCA and HRR status were observed in both low- and high-volume subgroups and were independent of treatment with androgen receptor pathway inhibitors or taxanes. CONCLUSION: Presence of HRR mutations, particularly BRCA alterations, significantly worsened prognosis, regardless of disease volume or treatment regimen. These findings underscore the importance of integrating tumour biology for accurate risk stratification in mHSPC and the design of new treatment strategies and follow-up.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Olmos D, Lorente D, Jambrina A, et al. BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes. Ann Oncol. 2025. PMID: 40467032. doi:10.1016/j.annonc.2025.05.534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。